Published in Psychopharmacology (Berl) on March 01, 2014
Disentangling the heterogeneity of autism spectrum disorder through genetic findings. Nat Rev Neurol (2014) 1.99
BDNF stimulation of protein synthesis in cortical neurons requires the MAP kinase-interacting kinase MNK1. J Neurosci (2015) 0.91
Location-dependent signaling of the group 1 metabotropic glutamate receptor mGlu5. Mol Pharmacol (2014) 0.85
Fragile X syndrome as a rare disease in China - Therapeutic challenges and opportunities. Intractable Rare Dis Res (2015) 0.83
Serotonin dysregulation in Fragile X Syndrome: implications for treatment. Intractable Rare Dis Res (2014) 0.80
Reduced phenotypic severity following adeno-associated virus-mediated Fmr1 gene delivery in fragile X mice. Neuropsychopharmacology (2014) 0.80
Disruption of mGluR5 in parvalbumin-positive interneurons induces core features of neurodevelopmental disorders. Mol Psychiatry (2015) 0.79
Rethinking metabotropic glutamate receptor 5 pathological findings in psychiatric disorders: implications for the future of novel therapeutics. BMC Psychiatry (2014) 0.78
Dysregulated nitric oxide signaling as a candidate mechanism of fragile X syndrome and other neuropsychiatric disorders. Front Genet (2014) 0.78
Autism spectrum disorders--an emerging area in psychopharmacology. Psychopharmacology (Berl) (2014) 0.77
mGluR5 Positive and Negative Allosteric Modulators Differentially Affect Dendritic Spine Density and Morphology in the Prefrontal Cortex. CNS Neurol Disord Drug Targets (2015) 0.77
Functional alterations of astrocytes in mental disorders: pharmacological significance as a drug target. Front Cell Neurosci (2015) 0.76
Delineating the Common Biological Pathways Perturbed by ASD's Genetic Etiology: Lessons from Network-Based Studies. Int J Mol Sci (2017) 0.75
β-Arrestin2 Couples Metabotropic Glutamate Receptor 5 to Neuronal Protein Synthesis and Is a Potential Target to Treat Fragile X. Cell Rep (2017) 0.75
Fragile X Syndrome: Prevalence, Treatment, and Prevention in China. Front Neurol (2017) 0.75
Discovery and characterization of a novel series of N-phenylsulfonyl-1H-pyrrole picolinamides as positive allosteric modulators of the metabotropic glutamate receptor 4 (mGlu4). Bioorg Med Chem Lett (2016) 0.75
Public Health Literature Review of Fragile X Syndrome. Pediatrics (2017) 0.75
Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell (1991) 17.00
The mGluR theory of fragile X mental retardation. Trends Neurosci (2004) 8.88
FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell (2011) 8.46
Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell (2001) 8.04
Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science (1991) 7.16
Absence of expression of the FMR-1 gene in fragile X syndrome. Cell (1991) 7.04
Correction of fragile X syndrome in mice. Neuron (2007) 6.51
Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A (2002) 6.45
A marker X chromosome. Am J Hum Genet (1969) 4.68
The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation. Nat Genet (1993) 4.57
Fmr1 knockout mice: a model to study fragile X mental retardation. The Dutch-Belgian Fragile X Consortium. Cell (1994) 4.43
The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses. Cell (2003) 4.34
Fragile X genotype characterized by an unstable region of DNA. Science (1991) 4.33
Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron (2012) 4.31
DNA methylation represses FMR-1 transcription in fragile X syndrome. Hum Mol Genet (1992) 4.22
Drosophila fragile X-related gene regulates the MAP1B homolog Futsch to control synaptic structure and function. Cell (2001) 4.21
Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology (2005) 4.09
Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. Proc Natl Acad Sci U S A (1997) 4.03
Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination. Am J Med Genet (2001) 3.77
Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med (2011) 3.46
Dendritic spine structural anomalies in fragile-X mental retardation syndrome. Cereb Cortex (2000) 3.43
2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology (1999) 3.25
Perisynaptic location of metabotropic glutamate receptors mGluR1 and mGluR5 on dendrites and dendritic spines in the rat hippocampus. Eur J Neurosci (1996) 3.22
Fragile X mental retardation protein: nucleocytoplasmic shuttling and association with somatodendritic ribosomes. J Neurosci (1997) 2.93
A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet (2009) 2.76
Analysis of neocortex in three males with the fragile X syndrome. Am J Med Genet (1991) 2.70
Tissue specific expression of FMR-1 provides evidence for a functional role in fragile X syndrome. Nat Genet (1993) 2.69
Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells. Nat Genet (1999) 2.59
Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome. J Neurophysiol (2006) 2.57
A new function for the fragile X mental retardation protein in regulation of PSD-95 mRNA stability. Nat Neurosci (2007) 2.54
Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis (2008) 2.52
Fragile X mice develop sensory hyperreactivity to auditory stimuli. Neuroscience (2001) 2.31
Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome. Genes Brain Behav (2005) 2.22
Molecular characterization of a novel metabotropic glutamate receptor mGluR5 coupled to inositol phosphate/Ca2+ signal transduction. J Biol Chem (1992) 2.21
Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet (2008) 2.20
(Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features. Hum Mol Genet (2000) 2.17
Evidence for social anxiety and impaired social cognition in a mouse model of fragile X syndrome. Behav Neurosci (2008) 2.10
The fragile X mental retardation syndrome protein interacts with novel homologs FXR1 and FXR2. EMBO J (1995) 2.05
Drosophila lacking dfmr1 activity show defects in circadian output and fail to maintain courtship interest. Neuron (2002) 2.03
Social approach in genetically engineered mouse lines relevant to autism. Genes Brain Behav (2008) 1.94
Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr (2008) 1.91
Fragile X mouse: strain effects of knockout phenotype and evidence suggesting deficient amygdala function. Neuroscience (1999) 1.91
Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome. J Neurosci (2010) 1.89
Elevated FMR1 mRNA in premutation carriers is due to increased transcription. RNA (2007) 1.87
Fragile X males with unmethylated, full mutation trinucleotide repeat expansions have elevated levels of FMR1 messenger RNA. Am J Med Genet (2000) 1.85
Fragile X syndrome. Eur J Hum Genet (2008) 1.81
Adult fragile X syndrome. Clinico-neuropathologic findings. Acta Neuropathol (1985) 1.80
Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome. PLoS One (2011) 1.75
Characterization of the full fragile X syndrome mutation in fetal gametes. Nat Genet (1997) 1.74
Enriched environment promotes behavioral and morphological recovery in a mouse model for the fragile X syndrome. Proc Natl Acad Sci U S A (2005) 1.70
Decreased expression of the GABAA receptor in fragile X syndrome. Brain Res (2006) 1.70
Nucleus basalis magnocellularis and hippocampus are the major sites of FMR-1 expression in the human fetal brain. Nat Genet (1993) 1.68
Normal phenotype in two brothers with a full FMR1 mutation. Hum Mol Genet (1995) 1.63
Regulation of metabotropic glutamate receptor signaling, desensitization and endocytosis. Pharmacol Ther (2006) 1.62
FXR1, an autosomal homolog of the fragile X mental retardation gene. EMBO J (1995) 1.61
The Drosophila fragile X gene negatively regulates neuronal elaboration and synaptic differentiation. Curr Biol (2004) 1.60
Decreased GABA(A) receptor expression in the seizure-prone fragile X mouse. Neurosci Lett (2004) 1.55
Synergistic effect of histone hyperacetylation and DNA demethylation in the reactivation of the FMR1 gene. Hum Mol Genet (1999) 1.53
A heterogeneous set of FMR1 proteins is widely distributed in mouse tissues and is modulated in cell culture. Hum Mol Genet (1995) 1.50
Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys. Am J Med Genet A (2010) 1.50
Modifying behavioral phenotypes in Fmr1KO mice: genetic background differences reveal autistic-like responses. Autism Res (2011) 1.49
Behavioral and neuroanatomical characterization of the Fmr1 knockout mouse. Hippocampus (2002) 1.48
Ablation of Fmrp in adult neural stem cells disrupts hippocampus-dependent learning. Nat Med (2011) 1.47
A reduced number of metabotropic glutamate subtype 5 receptors are associated with constitutive homer proteins in a mouse model of fragile X syndrome. J Neurosci (2005) 1.47
Metabotropic glutamate receptors and fragile x mental retardation protein: partners in translational regulation at the synapse. Sci Signal (2008) 1.45
Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. J Clin Psychopharmacol (1982) 1.43
Transport of fragile X mental retardation protein via granules in neurites of PC12 cells. Mol Cell Biol (2002) 1.42
Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome. Genes Brain Behav (2012) 1.41
The FMR1 gene and fragile X-associated tremor/ataxia syndrome. Am J Med Genet B Neuropsychiatr Genet (2009) 1.37
A PEDIGREE OF MENTAL DEFECT SHOWING SEX-LINKAGE. J Neurol Psychiatry (1943) 1.36
Contribution of mGluR and Fmr1 functional pathways to neurite morphogenesis, craniofacial development and fragile X syndrome. Hum Mol Genet (2006) 1.36
A mouse model of the human Fragile X syndrome I304N mutation. PLoS Genet (2009) 1.36
Neurodevelopmental effects of the FMR-1 full mutation in humans. Nat Med (1995) 1.35
The generation of a conditional Fmr1 knock out mouse model to study Fmrp function in vivo. Neurobiol Dis (2005) 1.34
Mildly impaired water maze performance in male Fmr1 knockout mice. Neuroscience (1997) 1.32
SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. J Pharmacol Exp Ther (1999) 1.31
The fragile X mental retardation protein-RNP granules show an mGluR-dependent localization in the post-synaptic spines. Mol Cell Neurosci (2007) 1.29
Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment potential. Neuropharmacology (2008) 1.28
Species-dependent posttranscriptional regulation of NOS1 by FMRP in the developing cerebral cortex. Cell (2012) 1.28
Cognitive dysfunction and prefrontal synaptic abnormalities in a mouse model of fragile X syndrome. Proc Natl Acad Sci U S A (2011) 1.26
mGluR5 negative allosteric modulators overview: a medicinal chemistry approach towards a series of novel therapeutic agents. Curr Top Med Chem (2011) 1.25
Altered mRNA transport, docking, and protein translation in neurons lacking fragile X mental retardation protein. Proc Natl Acad Sci U S A (2010) 1.25
Alterations in the auditory startle response in Fmr1 targeted mutant mouse models of fragile X syndrome. Brain Res (2002) 1.25
Fragile X mental retardation protein regulates the levels of scaffold proteins and glutamate receptors in postsynaptic densities. J Biol Chem (2009) 1.24
Psychometric study of the Aberrant Behavior Checklist in Fragile X Syndrome and implications for targeted treatment. J Autism Dev Disord (2012) 1.23
Timing of the absence of FMR1 expression in full mutation chorionic villi. Hum Genet (2002) 1.21
Temporal requirements of the fragile X mental retardation protein in the regulation of synaptic structure. Development (2008) 1.21
Population screening for fragile X. Lancet (1992) 1.20
Recent progress in the discovery and development of negative allosteric modulators of mGluR5. Curr Opin Drug Discov Devel (2009) 1.16
Interaction of the transcription factors USF1, USF2, and alpha -Pal/Nrf-1 with the FMR1 promoter. Implications for Fragile X mental retardation syndrome. J Biol Chem (2000) 1.16
Epigenetic analysis reveals a euchromatic configuration in the FMR1 unmethylated full mutations. Eur J Hum Genet (2008) 1.12
Cytoplasmic RNA-binding proteins and the control of complex brain function. Cold Spring Harb Perspect Biol (2012) 1.12
Differential epigenetic modifications in the FMR1 gene of the fragile X syndrome after reactivating pharmacological treatments. Eur J Hum Genet (2005) 1.09
Association of FMRP with ribosomal precursor particles in the nucleolus. Biochem Biophys Res Commun (1996) 1.05
Potential therapeutic interventions for fragile X syndrome. Trends Mol Med (2010) 1.05
The psychiatric presentation of fragile x: evolution of the diagnosis and treatment of the psychiatric comorbidities of fragile X syndrome. Dev Neurosci (2011) 1.05
A distinct DNA-methylation boundary in the 5'- upstream sequence of the FMR1 promoter binds nuclear proteins and is lost in fragile X syndrome. Am J Hum Genet (2009) 1.05
Altered maturation of the primary somatosensory cortex in a mouse model of fragile X syndrome. Hum Mol Genet (2012) 1.04
Fragile X mental retardation protein has a unique, evolutionarily conserved neuronal function not shared with FXR1P or FXR2P. Dis Model Mech (2010) 1.02
Nuclear organization of active and inactive chromatin domains uncovered by chromosome conformation capture-on-chip (4C). Nat Genet (2006) 11.02
Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat Genet (2011) 3.93
Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet (2006) 3.69
Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med (2011) 3.46
Heterozygous submicroscopic inversions involving olfactory receptor-gene clusters mediate the recurrent t(4;8)(p16;p23) translocation. Am J Hum Genet (2002) 3.09
Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells. Proc Natl Acad Sci U S A (2013) 2.99
A new function for the fragile X mental retardation protein in regulation of PSD-95 mRNA stability. Nat Neurosci (2007) 2.54
Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis (2008) 2.52
Proteomic analysis of exosomes isolated from human malignant pleural effusions. Am J Respir Cell Mol Biol (2004) 2.44
Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients. EMBO J (2010) 2.43
Molecular and clinical analyses of Greig cephalopolysyndactyly and Pallister-Hall syndromes: robust phenotype prediction from the type and position of GLI3 mutations. Am J Hum Genet (2005) 2.40
De novo mutations in ATP1A3 cause alternating hemiplegia of childhood. Nat Genet (2012) 2.34
The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. Brain (2012) 2.33
Elements of morphology: standard terminology for the head and face. Am J Med Genet A (2009) 2.15
XLMR genes: update 2007. Eur J Hum Genet (2008) 2.07
Murine hippocampal neurons expressing Fmr1 gene premutations show early developmental deficits and late degeneration. Hum Mol Genet (2010) 1.95
Clinical features of boys with fragile X premutations and intermediate alleles. Am J Med Genet B Neuropsychiatr Genet (2003) 1.90
Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet (2004) 1.89
The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice. Psychopharmacology (Berl) (2003) 1.83
FMR1: a gene with three faces. Biochim Biophys Acta (2009) 1.77
The spectrum of WRN mutations in Werner syndrome patients. Hum Mutat (2006) 1.75
CFC syndrome. Am J Med Genet A (2003) 1.74
Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease. Am J Hum Genet (2012) 1.71
The ring 14 syndrome: clinical and molecular definition. Am J Med Genet A (2009) 1.70
Mapping the Wolf-Hirschhorn syndrome phenotype outside the currently accepted WHS critical region and defining a new critical region, WHSCR-2. Am J Hum Genet (2003) 1.67
Germline mutations in DIS3L2 cause the Perlman syndrome of overgrowth and Wilms tumor susceptibility. Nat Genet (2012) 1.61
Microsatellite repeat instability and neurological disease. Bioessays (2009) 1.60
CGG-repeat length and neuropathological and molecular correlates in a mouse model for fragile X-associated tremor/ataxia syndrome. J Neurochem (2008) 1.59
Sequestration of DROSHA and DGCR8 by expanded CGG RNA repeats alters microRNA processing in fragile X-associated tremor/ataxia syndrome. Cell Rep (2013) 1.56
Diversity, parental germline origin, and phenotypic spectrum of de novo HRAS missense changes in Costello syndrome. Hum Mutat (2007) 1.56
TDP-43 pathology in familial frontotemporal dementia and motor neuron disease without Progranulin mutations. Brain (2007) 1.55
Ectopic expression of CGG containing mRNA is neurotoxic in mammals. Hum Mol Genet (2009) 1.54
Classification of familial amyotrophic lateral sclerosis by family history: effects on frequency of genes mutation. J Neurol Neurosurg Psychiatry (2012) 1.52
Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys. Am J Med Genet A (2010) 1.50
Cd1d-dependent regulation of bacterial colonization in the intestine of mice. J Clin Invest (2009) 1.49
Human PET studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688. J Nucl Med (2007) 1.48
Nicotine potentiation of brain stimulation reward reversed by DH beta E and SCH 23390, but not by eticlopride, LY 314582 or MPEP in rats. Psychopharmacology (Berl) (2001) 1.47
Quantitative analysis of DNA demethylation and transcriptional reactivation of the FMR1 gene in fragile X cells treated with 5-azadeoxycytidine. Nucleic Acids Res (2002) 1.47
Metabotropic glutamate 5 receptor blockade may attenuate cocaine self-administration by decreasing brain reward function in rats. Psychopharmacology (Berl) (2004) 1.47
Molecular dissection of the events leading to inactivation of the FMR1 gene. Hum Mol Genet (2004) 1.46
Transport of fragile X mental retardation protein via granules in neurites of PC12 cells. Mol Cell Biol (2002) 1.42
Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. J Clin Invest (2012) 1.42
On the nosology and pathogenesis of Wolf-Hirschhorn syndrome: genotype-phenotype correlation analysis of 80 patients and literature review. Am J Med Genet C Semin Med Genet (2008) 1.40
Widespread non-central nervous system organ pathology in fragile X premutation carriers with fragile X-associated tremor/ataxia syndrome and CGG knock-in mice. Acta Neuropathol (2011) 1.39
Fxr1 knockout mice show a striated muscle phenotype: implications for Fxr1p function in vivo. Hum Mol Genet (2004) 1.39
Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur J Hum Genet (2005) 1.38
A case of 45,X male: genetic reevaluation and hormonal and metabolic follow-up in adult age. Fertil Steril (2008) 1.38
Prevalence of SHANK3 variants in patients with different subtypes of autism spectrum disorders. Eur J Hum Genet (2012) 1.36
Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A (2010) 1.36
Cognitive decline, neuromotor and behavioural disturbances in a mouse model for fragile-X-associated tremor/ataxia syndrome (FXTAS). Behav Brain Res (2005) 1.36
Expression of the GABAergic system in animal models for fragile X syndrome and fragile X associated tremor/ataxia syndrome (FXTAS). Brain Res (2008) 1.35
Mutation in the AP4M1 gene provides a model for neuroaxonal injury in cerebral palsy. Am J Hum Genet (2009) 1.34
Expression profiling suggests underexpression of the GABA(A) receptor subunit delta in the fragile X knockout mouse model. Neurobiol Dis (2005) 1.34
Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. J Nucl Med (2006) 1.32
A genomic rearrangement resulting in a tandem duplication is associated with split hand-split foot malformation 3 (SHFM3) at 10q24. Hum Mol Genet (2003) 1.32
Mutation of the MAP kinase DYF-5 affects docking and undocking of kinesin-2 motors and reduces their speed in the cilia of Caenorhabditis elegans. Proc Natl Acad Sci U S A (2007) 1.31
Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res (2003) 1.31
Oral-facial-digital syndromes: review and diagnostic guidelines. Am J Med Genet A (2007) 1.29
Species-dependent posttranscriptional regulation of NOS1 by FMRP in the developing cerebral cortex. Cell (2012) 1.28
Progressive spatial processing deficits in a mouse model of the fragile X premutation. Behav Neurosci (2009) 1.28
Exosomal secretion of cytoplasmic prostate cancer xenograft-derived proteins. Mol Cell Proteomics (2009) 1.27
A fragile balance: FMR1 expression levels. Hum Mol Genet (2003) 1.27
Mutations in KANSL1 cause the 17q21.31 microdeletion syndrome phenotype. Nat Genet (2012) 1.25
Premutation CGG-repeat expansion of the Fmr1 gene impairs mouse neocortical development. Hum Mol Genet (2010) 1.24
Group II metabotropic and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats. J Pharmacol Exp Ther (2003) 1.20
Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: overlapping clinical manifestations with Costello syndrome. Am J Med Genet A (2007) 1.18
PRKAR1B mutation associated with a new neurodegenerative disorder with unique pathology. Brain (2014) 1.16
Further evidence that the rs1858830 C variant in the promoter region of the MET gene is associated with autistic disorder. Autism Res (2009) 1.16
Mouse models of fragile X-associated tremor ataxia. J Investig Med (2009) 1.15
Silencing the majority of cerebellar granule cells uncovers their essential role in motor learning and consolidation. Cell Rep (2013) 1.14
Evaluation of the metabotropic glutamate receptor subtype 5 using PET and 11C-ABP688: assessment of methods. J Nucl Med (2007) 1.14
Ubiquitin-positive intranuclear inclusions in neuronal and glial cells in a mouse model of the fragile X premutation. Brain Res (2010) 1.13
Different mechanisms cause imprinting defects at the IGF2/H19 locus in Beckwith-Wiedemann syndrome and Wilms' tumour. Hum Mol Genet (2008) 1.13
Knockout mouse model for Fxr2: a model for mental retardation. Hum Mol Genet (2002) 1.13
Epigenetic analysis reveals a euchromatic configuration in the FMR1 unmethylated full mutations. Eur J Hum Genet (2008) 1.12
A missense mutation in CASK causes FG syndrome in an Italian family. Am J Hum Genet (2009) 1.12
SOS1 mutations in Noonan syndrome: molecular spectrum, structural insights on pathogenic effects, and genotype-phenotype correlations. Hum Mutat (2011) 1.12
Fibroblast phenotype in male carriers of FMR1 premutation alleles. Hum Mol Genet (2009) 1.11
Induced expression of expanded CGG RNA causes mitochondrial dysfunction in vivo. Cell Cycle (2014) 1.10
AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord (2011) 1.10
mGluR5 antagonists: discovery, characterization and drug development. Curr Opin Drug Discov Devel (2008) 1.09
Differential epigenetic modifications in the FMR1 gene of the fragile X syndrome after reactivating pharmacological treatments. Eur J Hum Genet (2005) 1.09
AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome. Neurobiol Dis (2011) 1.09
Fragile X syndrome. Am J Med Genet C Semin Med Genet (2005) 1.07
Temporal ordering deficits in female CGG KI mice heterozygous for the fragile X premutation. Behav Brain Res (2010) 1.07
Rubinstein-Taybi Syndrome: spectrum of CREBBP mutations in Italian patients. BMC Med Genet (2006) 1.06
Potential therapeutic interventions for fragile X syndrome. Trends Mol Med (2010) 1.05
The challenges of clinical trials in fragile X syndrome. Psychopharmacology (Berl) (2013) 1.05
The use of microsatellite instability, immunohistochemistry and other variables in determining the clinical significance of MLH1 and MSH2 unclassified variants in Lynch syndrome. Cancer Biomark (2006) 1.04
Room-temperature hydrogen sensing with heteronanostructures based on reduced graphene oxide and tin oxide. Angew Chem Int Ed Engl (2012) 1.04
Motor deficits on a ladder rung task in male and female adolescent and adult CGG knock-in mice. Behav Brain Res (2011) 1.04
Oxazolone-induced enterocolitis in zebrafish depends on the composition of the intestinal microbiota. Gastroenterology (2009) 1.03
The use of a non-lethal tool for evaluating toxicological hazard of organochlorine contaminants in Mediterranean cetaceans: new data 10 years after the first paper published in MPB. Mar Pollut Bull (2003) 1.02
SMN transcript levels in leukocytes of SMA patients determined by absolute real-time PCR. Eur J Hum Genet (2010) 1.02